{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:47:40Z","timestamp":1788871660791,"version":"build-2803163510"},"reference-count":70,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003968","name":"Iran National Science Foundation (INSF)","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003968","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The National Health and Medical Research Council","award":["1019921"],"award-info":[{"award-number":["1019921"]}]},{"name":"The National Health and Medical Research Council","award":["1079369"],"award-info":[{"award-number":["1079369"]}]},{"name":"The National Health and Medical Research Council","award":["1003707"],"award-info":[{"award-number":["1003707"]}]},{"name":"The National Health and Medical Research Council","award":["1000967"],"award-info":[{"award-number":["1000967"]}]},{"name":"The National Health and Medical Research Council","award":["1020955"],"award-info":[{"award-number":["1020955"]}]},{"DOI":"10.13039\/501100003550","name":"Queensland Government","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003550","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.atherosclerosis.2015.03.016","type":"journal-article","created":{"date-parts":[[2015,3,16]],"date-time":"2015-03-16T03:18:01Z","timestamp":1426475881000},"page":"284-296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Impact of fibrate therapy on plasma plasminogen activator inhibitor-1: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"240","author":[{"given":"Amirhossein","family":"Sahebkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Simental-Mend\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Golledge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib1","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"European Association for Cardiovascular Prevention & Rehabilitation","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib2","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.plipres.2014.07.002","article-title":"Recent advances in pharmacotherapy for hypertriglyceridemia","volume":"56","author":"Sahebkar","year":"2014","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1758-5996-3-24","article-title":"Short-term effect of fenofibrate on C-reactive protein: a meta-analysis of randomized controlled trials","volume":"3","author":"Ye","year":"2011","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/14656566.2014.876992","article-title":"New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease","volume":"15","author":"Sahebkar","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib6","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/dom.12277","article-title":"Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease: tale of a roller-coaster","volume":"16","author":"Sahebkar","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0021-9150(94)90090-6","article-title":"The effects of fibrates on lipoprotein and hemostatic coronary risk factors","volume":"111","author":"Schonfeld","year":"1994","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00544015","article-title":"Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects","volume":"25","author":"Heller","year":"1983","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib9","doi-asserted-by":"crossref","first-page":"27307","DOI":"10.1074\/jbc.272.43.27307","article-title":"Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alphadeficient mice","volume":"272","author":"Peters","year":"1997","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib10","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1172\/JCI117717","article-title":"Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates","volume":"95","author":"Staels","year":"1995","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib11","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib12","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0140-6736(09)60698-X","article-title":"Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial","volume":"373","author":"Rajamani","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib13","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1172\/JCI11765","article-title":"PAI-1, fibrosis, and the elusive provisional fibrin matrix","volume":"106","author":"Loskutoff","year":"2000","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1538-7836.2004.00827.x","article-title":"Pleiotropic functions of plasminogen activator inhibitor-1","volume":"3","author":"Lijnen","year":"2005","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib15","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.2337\/dc07-0109","article-title":"Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis","volume":"30","author":"Targher","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib16","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1182\/blood-2002-07-2331","article-title":"Direct binding of Nur77\/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNF alpha-induced PAI-1 expression","volume":"101","author":"Gruber","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib17","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1161\/CIRCULATIONAHA.114.009273","article-title":"Ideal cardiovascular health: associations with biomarkers and subclinical disease and impact on incidence of cardiovascular disease in the framingham offspring study","volume":"130","author":"Xanthakis","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib18","first-page":"293","article-title":"Plasminogen activator inhibitor-1, free fatty acids, and insulin resistance in patients with myocardial infarction","volume":"6","author":"Gruzdeva","year":"2013","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib19","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ijcard.2014.11.001","article-title":"Circulating acute phase proteins in relation to extent and composition of coronary atherosclerosis and cardiovascular outcome: results from the ATHEROREMO-IVUS study","volume":"177","author":"Battes","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib20","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1161\/ATVBAHA.111.224386","article-title":"Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study","volume":"31","author":"Belalcazar","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib21","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1160\/TH08-03-0164","article-title":"Inhibition by fibrates of plasminogen activator inhibitor type-1 expression in human adipocytes and preadipocytes","volume":"101","author":"Zirlik","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib22","first-page":"729","article-title":"Extralipid effects of micronized fenofibrate in dyslipidemic patients","volume":"58","author":"Okopie\u0144","year":"2006","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib23","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/01.ATV.19.6.1577","article-title":"Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells","volume":"19","author":"Nilsson","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/BF00403280","article-title":"Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis","volume":"34","author":"Juhan-Vague","year":"1991","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib25","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/0268-9499(93)90068-7","article-title":"Fibrinolytic effect of gemfibrozil versus placebo administration in response to venous occlusion","volume":"7","author":"Avellone","year":"1993","journal-title":"Fibrinolysis"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1055\/s-0038-1645040","article-title":"Effects of gemfibrozil on lipids and haemostasis after myocardial infarction","volume":"63","author":"Andersen","year":"1990","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0268-9499(94)90246-1","article-title":"The decrease of plasminogen activator inhibitor after normalization of triglycerides during treatment with fibrates","volume":"8","author":"Keber","year":"1994","journal-title":"Fibrinolysis"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1161\/01.ATV.16.4.511","article-title":"Gemfibrozil treatment of combined hyperlipoproteinemia: no improvement of fibrinolysis despite marked reduction of plasma triglyceride levels","volume":"16","author":"Br\u00f6ijersen","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib29","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1055\/s-0038-1657709","article-title":"Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients","volume":"78","author":"Kockx","year":"1997","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib30","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib31","unstructured":"S. Green, Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated march 2011], The Cochrane Collaboration (2011)."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib32","series-title":"Comprehensive Meta-analysis Version 2","author":"Borenstein","year":"2005"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib33","series-title":"Methods for Meta-analysis in Medical Research","author":"Sutton","year":"2000"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib34","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1089\/dna.2012.1947","article-title":"Does PPAR\u03b3(2) Gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis","volume":"32","author":"Sahebkar","year":"2013","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib35","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/ptr.5045","article-title":"Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis","volume":"28","author":"Sahebkar","year":"2014","journal-title":"Phytother. Res."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib36","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses","volume":"326","author":"Song","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib37","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J.\u00a0Clin. Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib39","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0021-9150(98)00003-3","article-title":"Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia","volume":"138","author":"Durrington","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib40","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/(SICI)1096-9136(199810)15:10<870::AID-DIA680>3.0.CO;2-8","article-title":"Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in\u00a0vitro oxidizability","volume":"15","author":"O'Neal","year":"1998","journal-title":"Diabet. Med."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1055\/s-0037-1613826","article-title":"Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy","volume":"83","author":"Hamsten","year":"2000","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib42","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0021-9150(99)00283-X","article-title":"Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients","volume":"148","author":"Mussoni","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib43","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF02333013","article-title":"Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia","volume":"43","author":"Pazzucconi","year":"1992","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib44","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1734-1140(11)70588-6","article-title":"Hemostatic effects of bezafibrate and \u03c9-3 fatty acids in isolated hypertriglyceridemic patients","volume":"63","author":"Krysiak","year":"2011","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib45","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.atherosclerosis.2004.01.033","article-title":"Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis","volume":"174","author":"Kon Koh","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib46","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1210\/jc.2005-1615","article-title":"Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance","volume":"91","author":"Okopie\u0144","year":"2006","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib47","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2337\/dc08-2335","article-title":"Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia","volume":"32","author":"Pruski","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib48","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.2337\/dc10-0272","article-title":"Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes","volume":"33","author":"Krysiak","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib49","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1055\/s-0037-1613861","volume":"83","author":"Cortellaro","year":"2000","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib50","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/00005344-200001000-00022","article-title":"Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state","volume":"35","author":"Genest","year":"2000","journal-title":"J.\u00a0Cardiovasc. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib51","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib52","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0033-0620(91)90012-B","article-title":"Impaired fibrinolysis and risk of thromboembolism","volume":"34","author":"Wiman","year":"1991","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib53","doi-asserted-by":"crossref","first-page":"e68920","DOI":"10.1371\/journal.pone.0068920","article-title":"Plasminogen activator inhibitor-2 polymorphism associates with recurrent coronary event risk in patients with high HDL and C-reactive protein levels","volume":"8","author":"Corsetti","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib54","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.atherosclerosis.2012.06.062","article-title":"Plasminogen activator inhitor-1 associates with cardiovascular risk factors in healthy young adults in the Cardiovascular Risk in Young Finns Study","volume":"224","author":"Raiko","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib55","first-page":"331","article-title":"Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1","volume":"13","author":"Juhan-Vague","year":"1987","journal-title":"Diabete Metab."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib56","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0021-9150(89)90104-4","article-title":"Factor VII coagulant activity is strongly associated with plasma concentration of large lipoprotein particles in middle-aged men","volume":"76","author":"Mitropoulos","year":"1989","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib57","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1161\/01.CIR.85.5.1888","article-title":"Direct effects of gemfibrozil on the fibrinolytic system: diminution of synthesis of plasminogen activator inhibitor type I","volume":"85","author":"Fujii","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib58","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1161\/01.ATV.17.1.26","article-title":"Studies on the mechanism of fibrate-inhibited expression of plasminogen activator inhibitor-1 in cultured hepatocytes from cynomolgus monkey","volume":"17","author":"Arts","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib59","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1055\/s-0038-1648809","article-title":"Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls","volume":"72","author":"Chomiki","year":"1994","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib60","doi-asserted-by":"crossref","first-page":"860","DOI":"10.2337\/diab.46.5.860","article-title":"Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease","volume":"46","author":"Alessi","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib61","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s001250050868","article-title":"Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals","volume":"41","author":"Eriksson","year":"1998","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib62","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.thromres.2007.10.014","article-title":"Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?","volume":"122","author":"Lacut","year":"2008","journal-title":"Thromb. Res."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib63","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1472-8206.2004.00252.x","article-title":"Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study","volume":"18","author":"Lacut","year":"2004","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib64","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/eurheartj\/ehp556","article-title":"Statins, fibrates, and venous thromboembolism: a meta-analysis","volume":"31","author":"Squizzato","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib65","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1515\/cclm-2012-0078","article-title":"Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study","volume":"50","author":"Herrmann","year":"2012","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib66","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/ATVBAHA.108.183160","article-title":"Antiplatelet actions of statins and fibrates are mediated by PPARs","volume":"29","author":"Ali","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib67","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib68","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib69","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfi brozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2015.03.016_bib70","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.clinthera.2013.06.019","article-title":"New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes","volume":"35","author":"Sahebkar","year":"2013","journal-title":"Clin. Ther."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915015001768?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915015001768?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T18:09:30Z","timestamp":1598810970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915015001768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0021915015001768"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.03.016","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of fibrate therapy on plasma plasminogen activator inhibitor-1: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2015 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}